Biotech Startups

Mass Dynamics builds software systems for research teams to interpret complex biological data and make data-driven decisions. The company combines scientific rigor with user-focused product design by integrating scientists, engineers, and product builders in collaborative development.

2 investors

Materia Bioworks develops MAPS, an AI-powered platform for accelerating product development using bio-based and biodegradable materials. The system helps manufacturers and product developers optimize material formulations and explore sustainable material options to reduce R&D cycles.

2 investors

Materialize Bio develops a 3D manufacturing platform that processes natural biopolymers such as silk, collagen, chitosan, and alginate into complex shapes for medical and surgical applications. The company focuses on biomaterial innovations for use in medicine.

2 investors

Matrisome Bio is an oncology biotech developing therapies based on extracellular matrix (ECM) biology, using a protein engineering platform to target the tumor microenvironment. Its work spans multiple modalities including radioligand therapies.

2 investors

MattiQ accelerates materials science discovery using a platform for computational experimentation and design across energy, computing, transportation, and space industries.

2 investors

MBD (주식회사 엠비디) is a biotechnology company that describes itself as technology-driven and posts updates on its research and expanding disease indications.

2 investors

MBX Capital is an investment firm that backs companies in the "Deep Health" space, with a portfolio spanning biotech, therapeutics, diagnostics, and life sciences tooling.

2 investors

MC Sciences is a biotech company developing first-in-class mast cell therapeutics based on a discovered mast cell receptor, aimed at diseases across immunology, dermatology, respiratory, gastrointestinal, fibrotic and chronic inflammatory conditions such as chronic urticaria, systemic mastocytosis, COPD, asthma and MCAS. It develops both small- and large-molecule drugs and is headquartered in Germany with operations in Naples, Florida.

2 investors

mDETECT develops methylation- and NGS-based liquid biopsy tests to monitor metastatic cancer, aimed at clinical validation and commercial diagnostic use. The company's work centers on tracking disease in patients battling metastatic cancer.

2 investors

MDxHealth is a commercial-stage precision diagnostics company offering molecular diagnostic tests to guide the diagnosis and treatment of prostate cancer and other urologic diseases. Its tests use proprietary genetic, epigenetic, and molecular technologies and serve physicians, patients, payers, and providers.

2 investors

MedGenome provides genetic and molecular diagnostic testing across areas including reproductive care, rare hereditary conditions, oncology, and infectious diseases, and operates a CAP-accredited multiomics laboratory with high-throughput sequencing and a proprietary analytics platform. It serves clinicians, hospitals, and pharma partners primarily across India and South Asia.

2 investors

Medikine engineers cytokine mimetics — peptide-based therapeutics that mimic natural cytokines — to treat serious diseases, with a focus on immuno-oncology. The company develops optimized therapies based on cytokine mimesis for clinical use.

2 investors

MedPharm is a contract development and manufacturing organization (CDMO) focused on topical, transdermal, and transepithelial drug products, supporting formulation development, in vitro testing, and GMP manufacturing from early development through commercial supply. It serves pharmaceutical and biotechnology companies, with facilities in Guildford, UK, and Durham, North Carolina, USA.

2 investors

Meduloc develops minimally invasive intramedullary implants for internal fixation of small and long-bone fractures. Its products are intended for orthopedic surgeons treating fracture patients in the medical device field.

2 investors

Meep develops biological monitoring technology to enable frequent clinical-grade testing for chronic disease patients, reducing unnecessary hospitalizations and intensive care admissions.

2 investors

Boston-based developer of an in vitro diagnostic test for diabetes based on the glycated CD59 (GCD59) biomarker.

2 investors

Mercator MedSystems develops catheter-based Micro-Infusion technologies, including the Bullfrog Micro-Infusion Device, for the local delivery of pharmacologic and biologic agents to the peripheral vasculature. The medical device company runs clinical studies in deep vein thrombosis and below-the-knee peripheral arterial disease, with applications in cardiovascular treatment and denervation for hypertension.

2 investors

Merck is a science-led pharmaceutical company that develops medicines and vaccines for patients globally. The company focuses on innovation and long-term value creation through its research pipeline and commitment to healthcare advancement.

2 investors

DARA's Result Interpretation Module provides a digitalized workflow that replaces manual document handling processes for specialists, eliminating printing, scanning, email distribution, and courier services in healthcare result management.

2 investors

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures. The company advances agonist antibody programs and operates a RAFT target discovery platform to identify new therapeutic targets.

2 investors

Mestastop develops research platforms and assays to study cancer metastasis biology and support early diagnosis and drug development. The company serves oncology researchers and pharmaceutical companies developing metastasis-prevention therapies.

2 investors

Meta-Flux builds in silico simulation software that models disease biology — cellular state, perturbation response, and therapeutic intervention — using mechanistic models grounded in public reference atlases and proprietary multi-omic data from partner biobanks. The platform targets drug discovery in neurodegeneration (Parkinson's, Alzheimer's, ALS, MSA) and immuno-oncology (breast, lung, melanoma, colorectal) to improve target selection and patient stratification.

2 investors

Metabolomic Diagnostics develops diagnostic tests using mass spectrometry and biomarker analysis, with a focus on women's health and pregnancy-related diseases. The company serves clinical laboratories and healthcare professionals through analytical innovation and diagnostic assay development.

2 investors

Metaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.

2 investors